托珠单抗治疗机械通气COVID-19患者的临床结局
该回顾性队列分析纳入2020年3月24日至5月4日休斯顿6家医院9个ICU连续62例接受托珠单抗的有创机械通气COVID-19患者,托珠单抗按4-8 mg/kg体重或固定400 mg给药,部分患者由医生决定重复给药。主要终点为死亡和临床改善(拔管)。托珠单抗后21天,36例(58%)临床改善,13例(21%)死亡;单变量和多变量分析均显示年龄<60岁与临床改善相关;短暂性转氨酶升高是最常见不良反应,发生于25例(40%)。作者认为托珠单抗是重症COVID-19管理策略中有前景的选择,并支持开展随机对照试验验证。
要点
- 62例有创机械通气COVID-19患者接受托珠单抗后21天,36例(58%)拔管,13例(21%)死亡。
- 单变量和多变量分析均显示年龄<60岁与临床改善(拔管)相关。
- 托珠单抗给药方案为按体重4-8 mg/kg或固定400 mg,部分患者由医生决定重复给药。
- 短暂性转氨酶升高为最常见不良反应,25例(40%)发生。
- 作者结论为托珠单抗是重症COVID-19管理中有前景的选择,支持开展随机对照试验。
适用人群与场景
- 连续62例COVID-19有创机械通气患者,来自2020年3月24日至5月4日休斯顿6家医院9个ICU,托珠单抗考虑用于所有重症患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 托珠单抗按体重4-8 mg/kg或固定剂量400 mg给药,部分患者由医生决定重复给药。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 回顾性队列分析,62例有创机械通气COVID-19患者,来自6家医院9个ICU,接受托珠单抗(4-8 mg/kg或400 mg,部分重复给药);托珠单抗后21天临床改善(拔管)36例(58%),死亡13例(21%)。
- 单变量和多变量分析均显示年龄<60岁与临床改善相关。
- 短暂性转氨酶升高为最常见不良反应,25例(40%)发生。
证据类型、等级与局限
- 证据类型:回顾性队列分析;原文未给出证据等级或推荐强度;原文未述局限性。
对床旁实践的改变
- 原文结论:基于既往报告的机械通气患者临床结局和死亡率,托珠单抗作为重症COVID-19管理策略的一部分是有前景的选择,支持开展随机对照试验评估。
指南或共识出处
- Crit Care Explor
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Effective treatments for the critically ill patient with novel coronavirus disease 2019 are desperately needed. Given the role of cytokine release syndrome in the pathogenesis of coronavirus disease 2019-associated respiratory distress, therapies aimed at mitigating cytokine release, such as the interleukin-6 receptor-inhibiting monoclonal antibody tocilizumab, represent potential treatment strategies. Therefore, we examined the outcomes of critically ill coronavirus disease 2019 patients treated with tocilizumab and factors associated with clinical improvement.
DESIGN: A retrospective cohort analysis of 21-day outcomes for consecutive mechanically ventilated patients treated with tocilizumab from March 24, 2020, to May 4, 2020.
SETTING: Nine ICUs at six hospitals within a hospital system in Houston, Texas, United States.
PATIENTS: The first 62 coronavirus disease 2019 patients on invasive mechanical ventilation who were treated with tocilizumab, which was considered for all patients with severe disease.
INTERVENTIONS: Tocilizumab was administered either at a weight-based dose of 4-8 mg/kg or at a flat dose of 400 mg, with repeat administration in some patients at the physician's discretion.
MEASUREMENTS AND MAIN RESULTS: The primary outcomes were mortality and clinical improvement, defined as extubation. By day 21 post-tocilizumab, clinical improvement occurred in 36 patients (58%) and 13 patients (21%) died. In both univariable and multivariable analyses, age less than 60 years was associated with clinical improvement. Transient transaminitis was the most common adverse reaction, occurring in 25 patients (40%).
CONCLUSIONS: Based on clinical outcomes and mortality rates seen in previous reports of mechanically ventilated patients, tocilizumab, as part of the management strategy for severe coronavirus disease 2019, represents a promising option. These findings support the need for evaluation of tocilizumab in a randomized controlled trial.
参考来源
- Sirimaturos M, Gotur DB, Patel SJ, et al. Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients. Crit Care Explor. 2020. PMID: 33063035. doi:10.1097/CCE.0000000000000232
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。